« Alzheimer's: Extracting Data From Failed Trials |
| Looking Back at the Genome »
June 11, 2010
Eli Lilly, Meet Eli Lilly. Topic: Outsourcing!
Eli Lilly has been very aggressive about outsourcing their R&D work. A look at their headlines over the last few years confirms that impression. "Lilly's Labs Go Global" (2006). "Eli Lilly to Outsource Half of Research by 2010"http://www.fiercebiotech.com/story/eli-lilly-outsource-half-research-2010/2007-12-17 (2007). "Covance Inks 1.6B Dollar Deal With Lilly" (2008). Here's an overview of the whole process.
Comes now a highly placed pharma executive warning about America's competitive edge in the life sciences:
The American pharmaceutical and life sciences industry is in danger of losing its edge in innovation, said John Lechleiter, chairman and CEO of Eli Lilly & Co. today at the Detroit Economic Club.
Lechleiter blamed the loss on tax and immigration policies over the last 10 years that have reduced research and investment funding and driven away foreign-born, U.S.-trained scientists.
Now, as regular readers know, I'm not an opponent of outsourcing. But you can't have it both ways, sending as much research and development as you can to India, China, and what have you, and then complaining about the US losing its R&D position. Can you?
+ TrackBacks (0) | Category: Business and Markets
POST A COMMENT
- RELATED ENTRIES
- How Not to Do It: NMR Magnets
- Allergan Escapes Valeant
- Vytorin Actually Works
- Fatalities at DuPont
- The New York TImes on Drug Discovery
- How Are Things at Princeton?
- Phage-Derived Catalysts
- Our Most Snorted-At Papers This Month. . .